Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
gastrointestinal neoplasms | — | D005770 | C26.9 |
Expiration | Code | ||
---|---|---|---|
trastuzumab deruxtecan, Enhertu, Daiichi Sankyo, Inc | |||
2028-01-15 | Orphan excl. |
Code | Description |
---|---|
J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 12 | 8 | 1 | 3 | 32 |
Neoplasms | D009369 | — | C80 | 1 | 3 | — | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 5 | 5 | 1 | — | — | 9 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 4 | 3 | 1 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 3 | 4 | — | — | — | 5 |
Triple negative breast neoplasms | D064726 | — | — | 2 | 4 | — | — | — | 4 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | 1 | 3 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 2 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 1 | — | — | — | 2 |
Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
Hemangiosarcoma | D006394 | — | — | — | 1 | — | — | — | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 1 | — | — | — | — | 1 |
Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
Agranulocytosis | D000380 | HP_0012234 | D70 | — | — | — | — | 1 | 1 |
Opportunistic infections | D009894 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Trastuzumab deruxtecan |
INN | trastuzumab deruxtecan |
Description | Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized by the cell, carrying the bound deruxtecan along with it, where it interferes with the cell's ability to make DNA structural changes and replicate its DNA during cell division, leading to DNA damage when the cell attempts to replicate itself, destroying the cell.
|
Classification | Antibody |
Drug class | monoclonal antibodies; antineoplastics (camptothecin derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1826843-81-5 |
RxCUI | — |
ChEMBL ID | CHEMBL4297844 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB14962 |
UNII ID | 5384HK7574 (ChemIDplus, GSRS) |